June 9, 2021 7:41am

Pricing pressures are about to become more speculative without news

Annual Oncology (ASCO) Meetings and presentations this week

Pre-open indications: 2 BUYs: AGTC, CRSP; 8 SELLs into Strength - Profit: AXGN, KDNY, EDIT, FATE, IONS, GBT, MESO, SAGE; 2 Maintain SELLs: FIXX, BSTG

My version of the morning’s “indications” is about what you need to know; it’s what could happen or materialize after the opening and what might happen during the session

Subscription is coming, it’s not conscription but, an offer to join our collective of like-minded investors!  


Dow futures are DOWN -0.10% (-35 points), S&P futures are UP +0.06% (+3 point) and NASDAQ futures are UP +0.30% (+40 points)

 

Stock futures were flat pre-open on Wednesday

European stocks were muted,

Asia-Pacific stocks were mostly lower as investors reacted to the release of Chinese inflation data.

 

Henry’omics:

Trading was quiet in the pre-market …

The S&P 500 and the blue-chip Dow both closed near the flatline on Tuesday as the cell and gene therapy sector rolled upwards after a mid-day trip.

 

RegMed/Cell and Gene Therapy Earnings Scorecard Q1/21 LPS Results … thirty (32 – MESO added) to date …  https://www.regmedinvestors.com/articles/11628

 

Tuesday’s evening’s recap: “barely trimming the upside while volume remains weak. Sector recovers as the mid-day unfolds to close positive.” … https://www.regmedinvestors.com/articles/11946

  • The Nasdaq closed UP +43.19 points (+0.31%);
  • The IBB closed down -0.13% and XBI closed up +0.64%
  • Sector volume was WEAK with 7 of the 25-upside having higher than the 3-month average volume with the volume of 2 of 9-downside having higher than the 3-month average volume;
  • The CBOE Volatility Index (VVIX: INDEX) was up +0.65 points or +3.96% at 17.07;
  • Tuesday’s percentage (%) of the 25-upside were +0.24% (AGTC) to +11.50% (BSTG) while the 9-downside ranges from -0.24% (CRSP) to -4.57% (BCLI);

Q2/21:

June: 4 positive and 2 negative close

May:  8 positive, 12 negative closes and 1 holiday

April: 11 negative and 10 positive closes

Q1/21:

  • March: 10 positive, 12 negative and 1 neutral closes
  • February: 9 positive, 10 negative closes and 1 holiday
  • January: 10 positive, 9 negative closes and 1 holiday

 

Companies in my headlights – It’s your decision; I provide an idea and context:

The Biostage (BSTG) - Maintaining Sell – It’s about saying WHAT NEEDS to be written …

Biostage (BSTG) closed up +$0.13 to $1.26 with 1,216 shares traded after Tuesday’s -$0.17 to $1.13 with 2,320 shares traded, Friday’s +$0.19 to $1.30 with 800 shares traded, Thursday’s flat with 3,528 shares traded and last Wednesday’s -0.11 to $1.11 with 5,673 shares traded.

Question#`1: Notice the volume numbers per session? WHY the need to “pump, promote and inflate” the share price; does the volume reflects the manipulation to execute the last remaining warrants?

MINORITY PUBLIC shareholders are waiting, watching and weighing responses to MAINTAIN their RIGHTS.

 

The morning’s indications:

SELL into Strength: for profit …

AxoGen (AXGN) closed up +$0.54 to $19.86 with a positive +$0.46 or =2.32% aftermarket indication.

Chinook Therapeutics (KDNY) closed up =$0.91 to $18.50 with a positive =$1.00 or +5.41% aftermarket indication.

Editas Medicine (EDIT) closed up +$0.48 to $35.99 after Monday’s +$1.84 to $35.51 after Friday’s +$0.51 to $33.67 and has a positive +$0.51 or +1.42% pre-market indication.

Fate Therapeutics (FATE) closed up +$2.23 to $79.23 and has a negative -$0.78 or -0.98% pre-market indication.

Ionis Pharmaceuticals (IONS) closed up +$1.02 to $36.89 after Monday’s +$1.33 to $35.87 and has a positive +$0.11 or +0.30% pre-market indication.

Global Blood Therapeutics (GBT) closed up +$1.08 to $40.93 after Monday’s +$0.84 to $39.85 after Friday’s +$0.74 to $39.00 and has a positive +$0.77 or +1.88% aftermarket indication.

Mesoblast (MESO) closed up +$0.54 to $7.61 with a positive +$0.19 or +2.50% aftermarket indication.

Sage Therapeutics (SAGE) closed up +$4.29 to $74.76 and has a positive +$0.08 or +0.11% pre-market indication.

 

Maintaining SELL:

Homology Medicine (FIXX) closed up +$0.07 to $6.85 after Monday’s +$0.25 to $6.78 and Friday’s -$0.02 to $6.53 and has a negative -$0.13 or -1.90% aftermarket indication.

 

BUY:

Applied Genetic Technologies (AGTC) closed up +$0.01 to $4.17 after Monday’s +$0.12 to $4.16 with a positive +$0.05 or +1.20% pre-market indication.

CRISPR Therapeutics (CRSP) closed down -$0.29 to $118.91 after Monday’s +$5.91 to $119.20 and Friday’s +$3.16 to $113.29 and has a positive +$2.32 or +1.95% pre-market indication.

 

The BOTTOM LINE: Wake-up volatility is NOT going away!

I continue to MAINTAIN, this is a confused sector as sentiment fades, momentum is usurped, fundamentals are being ignored – or is it a test of our staying power in certain equities.

It’s going be a long hot summer – expects the fizzle on stock pricing until it isn’t!

Although, “I would consider new highs … to be SOLD into …complacency is in store as many investors actually get out to vacations (one indicator).”

A true contrarian thought …

My focus has always been “warning analysis” … my advice, trim and skim any new highs if one can!” I also see a number of lows that could be in the “pick-up” stock game.

My motto, never leave an investor uninformed about what I know!

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.